Macrolides for the Treatment of Chronic Sinusitis,Asthma,and COPD Mark H. Gotfried,, MD, FCCP (CHEST 2004; 125:52S-61S) Ri 邱立忠

Size: px
Start display at page:

Download "Macrolides for the Treatment of Chronic Sinusitis,Asthma,and COPD Mark H. Gotfried,, MD, FCCP (CHEST 2004; 125:52S-61S) Ri 邱立忠"

Transcription

1 Macrolides for the Treatment of Chronic Sinusitis,Asthma,and COPD Mark H. Gotfried,, MD, FCCP (CHEST 2004; 125:52S-61S) Ri 邱立忠

2 Abstract Sinusitis:mucociliary clearance,sinusitis symptoms,nasal secretions/polyp size, inflammatory response. Asthma:airway hyperresponsiveness, pulmonary function,"steroid-sparing" effect. COPD:symptom scores, FEV 1

3 Summary of Effects of Macrolides Relevant to Respiratory Tract Inflammation Inhibit synthesis/secretion of proinflammatory cytokines Effects on neutrophils Decrease neutrophil oxidative burst Inhibit neutrophil migration (chemotaxis) to inflammatory sites Increase apoptosis of neutrophils (?) Neutrophil degranulation (?) Inhibit neutrophil adhesion Inhibit phagocytosis

4 Summary of Effects of Macrolides Relevant to Respiratory Tract Inflammation Eosinophilic inflammation Mucociliary transport Goblet cell secretion Bronchoconstriction endothelin-1 release,cholinergic responses of airway smooth muscle

5 Benefit of Macrolides on respiratory tract diseases Anti-inflammatory benefits? Antimicrobial action?

6 Chronic Sinusitis Anti-inflammatory inflammatory benefits (1) First article:1996, Hashiba and Baba 45 p ts,clarithromycin400 mg daily 8-12 weeks (or roxithromycin,150 mg daily) symptoms,rhinoscopic findings improved α duration Improvement rates:5%/48%/63%/71% after 2/4/8/12 weeks therapy

7 Chronic Sinusitis Anti-inflammatory inflammatory benefits After 12 weeks of therapy: 64% : viscosity of nasal secretions 56% :quantity of nasal secretions 62%:postnasal drip 51%: nasal obstruction

8 Chronic Sinusitis Anti-inflammatory inflammatory benefits (2) 1997,Rubin :Nasal mucus properties 10healthyVS10 p ts clarithromycin, 500 mg twice daily for 2 weeks Before therapy: secretions from p ts wetability/sneeze clearability ; solids and cohesion (VS healthy)

9 Chronic Sinusitis Anti-inflammatory inflammatory benefits After therapy:secretions of healthy/ p ts:similar(~rheology, hydration, cohesion,transportability) Methacholine secretory response :not affected Effect on mucus properties :based on the modulation of inflammation.

10 Chronic Sinusitis Anti-inflammatory inflammatory benefits Prospective, open-label study at a single center in USA :25 p ts (mean age:45 y/o), clarithromycin, 500 mg twice daily for 14 days Biopsy of the maxillary sinus mucosa (Before VS 7 days after treatment)

11 Chronic Sinusitis Anti-inflammatory inflammatory benefits Markers of sinus mucosal inflammation :macrophages (CD68)/elastase/IL-6, IL-8/TNF-α/activity of eosinophils (EG2) clarithromycin may modulates the immune response Edema score :41%,clinical signs and symptoms 1 and 2week F/U : improved

12 Chronic Sinusitis Anti-inflammatory inflammatory benefits Yamada: effect on the size of nasal polyps / IL-8 levels in nasal lavage fluid. 20 p ts (24-84 y/o; mean age:57 y/o) clarithromycin, 400 mg daily 8 to 12 weeks P ts (polyps size ) during therapy, IL-8 levels (significantly) at baseline more than fivefold

13 Chronic Sinusitis Anti-inflammatory inflammatory benefits P ts :polyps size(-)after therapy:il-8 (-) before/after therapy Ichimura: 20 p ts,nasal polyps with CPS roxithromycin, 150 mg daily for 8 weeks: > 50% polyp size Nasal polyps αsuppression of cytokine production

14 Asthma Anti-inflammatory inflammatory benefits Amayasu :bronchoconstriction caused by inhalation of methacholine, 17 p ts,clarithromycin, 200 mg,twice daily for 8 weeks, After 8 weeks treatment symptoms,blood/sputum eosinophil, sputum eosinophilic cationic protein, bronchial hyperresponsiveness

15 Asthma Anti-inflammatory inflammatory benefits This paper:21 p ts with corticosteroid-dep asthma(ie 5 mg prednisone for 6 months before study) clarithromycin, 500 mg twice daily for 6 weeks FVC,FEV 1,nocturnal dyspnea, social concerns,chest discomfort

16 Asthma Anti-inflammatory inflammatory benefits Nighttime symptoms : marker for inflammation clinical benefit αanti-inflammatory effects During study: steroid dosage(-) majority:reduced two elderly p ts: discontinued

17 Asthma Anti-inflammatory inflammatory benefits Anti-inflammatory bronchial effect also has been reported with roxithromycin (Kamoi and Shoji T,Yoshida S,Sakamoto H) 2 months therapy required for demonstrable clinical improvement!!

18 Asthma Antimicrobial action Atypical intracellular pathogens (Chlamydia pneumoniae/mycoplasma pneumoniae):pathogenesis of reactive airway diseases.? M pneumoniae or C pneumoniae in > 50% stable chronic asthma airways (CHEST2002;121:1782-8)

19 Asthma Clinical Experience The benefit of Macrolides in some asthma p ts Anti-inflammatory or Antimicrobial effects???????

20 Asthma Clinical Experience Kraft: 52 p ts,clarithromycin,500 mg,twice daily for 6 weeks mean FEV 1 levels (2.50 ± 0.16 L)to(2.69 ± 0.19 L) Chlamydia(+) or Mycoplasma(+) No improvement in FEV 1: PCR(-) Inflammatory mediators (IL-5, IL-12, TNF-α), eosinophil/neutrophil levels in bronchoalveolar lavage fluid (immunomodulatory activity )

21 Asthma Clinical Experience Black :232 p ts,c.pneumoniae(+)roxithromycin150 mg, twice daily After 6 weeks of therapy : nighttime PEF, daytime PEF:(-) ( disappeared within 3 months stopping therapy!) Macrolide :temporarily chlamydial infection,infection/sequelae after stopping therapy!!

22 COPD Clinical Experience Banerjee :moderate-to-severe COPD ( FEV 1 < 60%) clarithromycin, 500 mg daily (24 p ts)vs placebo (33 p ts) for 3 months of therapy sputum total cell count/inflammatory cytokine levels/sputum pathogen count :No changed!! Total cell count/absolute neutrophil count VS total health status impact, respiratory symptoms,activity scores:significant,not to pulmonary function (Eur Respir J 2001;18:94S)

23 COPD Clinical Experience Nixon: 25 p ts,copd with exacerbation, clarithromycin, 500 mg twice daily for 2 weeks Absolute FEV 1 :1.12 L 1.34 L posttreatment, the mean total scores for signs/symptoms : Improvement in symptoms After 1 week: most profound; After 2 week sustained. After 4 week :continued (not significant)

24 Discussion Macrolides for COPD: to be determined!! Macrolides on respiratory tract diseases :anti-inflammatory benefits or antimicrobial action: debate!! Large-scale/placebo-controlled studies:needed!!

25 Thank you for your attention!!

Compare the physiologic responses of the respiratory system to emphysema, chronic bronchitis, and asthma

Compare the physiologic responses of the respiratory system to emphysema, chronic bronchitis, and asthma Chapter 31 Drugs Used to Treat Lower Respiratory Disease Learning Objectives Describe the physiology of respirations Compare the physiologic responses of the respiratory system to emphysema, chronic bronchitis,

More information

Diagnosis & Treatment Of Cough

Diagnosis & Treatment Of Cough Diagnosis & Treatment Of Cough a.diagnosis : - Details History - Physical Examination - Investigation b. Treatment of cough Detail history provides valuables clues for etiology of the cough - Acute or

More information

Objectives COPD. Chronic Obstructive Pulmonary Disease (COPD) 4/19/2011

Objectives COPD. Chronic Obstructive Pulmonary Disease (COPD) 4/19/2011 Objectives Discuss assessment findings and treatment for: Chronic Obstructive Pulmonary Disease Bronchitis Emphysema Asthma Anaphylaxis Other respiratory issues Provide some definitions Chronic Obstructive

More information

Asthma (With a little SCID to start) Disclosures Outline Starting with the Immune System The Innate Immune System The Adaptive Immune System

Asthma (With a little SCID to start) Disclosures Outline Starting with the Immune System The Innate Immune System The Adaptive Immune System 1 2 3 4 5 6 7 8 9 Asthma (With a little SCID to start) Lauren Smith, MD CHKD Pediatric Allergy/Immunology Disclosures None Will be discussing some medications that are not yet FDA approved Outline SCID

More information

Pharmacology of the Respiratory Tract: COPD and Steroids

Pharmacology of the Respiratory Tract: COPD and Steroids Pharmacology of the Respiratory Tract: COPD and Steroids Dr. Tillie-Louise Hackett Department of Anesthesiology, Pharmacology and Therapeutics University of British Columbia Associate Head, Centre of Heart

More information

Pulsating Aerosol. The New Wave in SINUSitis Therapy. Cystic Fibrosis. Focus on. For the precise, effective and gentle treatment of sinusitis

Pulsating Aerosol. The New Wave in SINUSitis Therapy. Cystic Fibrosis. Focus on. For the precise, effective and gentle treatment of sinusitis The New Wave in SINUSitis Therapy Focus on Cystic Fibrosis Pulsating Aerosol For the precise, effective and gentle treatment of sinusitis PARI SINUS Inhalation treatment for acute and chronic diseases

More information

Idiopathic Pulmonary Fibrosis (IPF) Research

Idiopathic Pulmonary Fibrosis (IPF) Research Idiopathic Pulmonary Fibrosis (IPF): Why Early Referral is Critical Even if Your Patient is Not Eligible for a Clinical Trial Idiopathic Pulmonary Fibrosis (IPF) Research Management of IPF requires a confident

More information

Prevention of Acute COPD exacerbations

Prevention of Acute COPD exacerbations December 3, 2015 Prevention of Acute COPD exacerbations George Pyrgos MD 1 Disclosures No funding received for this presentation I have previously conducted clinical trials with Boehringer Ingelheim. Principal

More information

Pulsating Aerosol. The New Wave in SINUSitis Therapy. For the precise, effective and gentle treatment of sinusitis

Pulsating Aerosol. The New Wave in SINUSitis Therapy. For the precise, effective and gentle treatment of sinusitis The New Wave in SINUSitis Therapy Pulsating Aerosol For the precise, effective and gentle treatment of sinusitis PARI SINUS Inhalation treatment for acute and chronic diseases of the upper airways www.parimedical.co.uk

More information

Breathe Easy: Asthma and FMLA

Breathe Easy: Asthma and FMLA This article was published in the FMLA Policy, Practice, and Legal Update newsletter, by Business & Legal Reports, Inc. (BLR). BLR is a nationally recognized publisher of regulatory and legal compliance

More information

Hypersensitivity. TYPE I Hypersensitivity Classic allergy. Allergens. Characteristics of allergens. Allergens. Mediated by IgE attached to Mast cells.

Hypersensitivity. TYPE I Hypersensitivity Classic allergy. Allergens. Characteristics of allergens. Allergens. Mediated by IgE attached to Mast cells. Gel and Coombs classification of hypersensitivities. Hypersensitivity Robert Beatty Type I Type II Type III Type IV MCB150 IgE Mediated IgG/IgM Mediated IgG Mediated T cell Classic Allergy rbc lysis Immune

More information

Influenza (Flu) Influenza is a viral infection that may affect both the upper and lower respiratory tracts. There are three types of flu virus:

Influenza (Flu) Influenza is a viral infection that may affect both the upper and lower respiratory tracts. There are three types of flu virus: Respiratory Disorders Bio 375 Pathophysiology General Manifestations of Respiratory Disease Sneezing is a reflex response to irritation in the upper respiratory tract and is associated with inflammation

More information

RSPT 2317 Non-steroidal anti-asthma agents

RSPT 2317 Non-steroidal anti-asthma agents RSPT 2317 Non-steroidal Anti-asthma Agents Mechanisms of Inflammation in Asthma Mechanisms of Inflammation in Asthma Asthma is a chronic inflammatory disorder of the airways It is divided into extrinsic

More information

Asthma Definition. Relationship of Airway Inflammation and Lung Function

Asthma Definition. Relationship of Airway Inflammation and Lung Function Asthma Guidelines Goals of Medical Care for Adults and Children with Asthma Source: National Institutes of Health, National Heart Lung, and Blood Institute, National Asthma Education and Prevention Program

More information

PLAN OF ACTION FOR. Physician Name Signature License Date

PLAN OF ACTION FOR. Physician Name Signature License Date PLAN OF ACTION FOR Patient s copy (patient s name) I Feel Well Lignes I feel short directrices of breath: I cough up sputum daily. No Yes, colour: I cough regularly. No Yes I Feel Worse I have changes

More information

2.06 Understand the functions and disorders of the respiratory system

2.06 Understand the functions and disorders of the respiratory system 2.06 Understand the functions and disorders of the respiratory system 2.06 Understand the functions and disorders of the respiratory system Essential questions What are the functions of the respiratory

More information

Montelukast Sodium. -A new class of seasonal allergic rhinitis therapy

Montelukast Sodium. -A new class of seasonal allergic rhinitis therapy Montelukast Sodium -A new class of seasonal allergic rhinitis therapy Symptoms of Seasonal Allergic Rhinitis Nasal itch Sneezing Rhinorrhoea Nasal stuffiness Pathogenesis of Allergic Rhinitis Mast cells,

More information

EMPHYSEMA THERAPY. Information brochure for valve therapy in the treatment of emphysema.

EMPHYSEMA THERAPY. Information brochure for valve therapy in the treatment of emphysema. EMPHYSEMA THERAPY Information brochure for valve therapy in the treatment of emphysema. PATIENTS WITH EMPHYSEMA With every breath, lungs deliver oxygen to the rest of the body to perform essential life

More information

How to use FENO-guided asthma control in routine clinical practice

How to use FENO-guided asthma control in routine clinical practice How to use FENO-guided asthma control in routine clinical practice Asthma is a chronic inflammatory disease of the airways. This has implications for the diagnosis, management and potential prevention

More information

Drug therapy SHORT-ACTING BETA AGONISTS SHORT-ACTING ANTICHOLINERGICS LONG-ACTING BETA AGONISTS LONG-ACTING ANTICHOLINERGICS

Drug therapy SHORT-ACTING BETA AGONISTS SHORT-ACTING ANTICHOLINERGICS LONG-ACTING BETA AGONISTS LONG-ACTING ANTICHOLINERGICS Drug therapy 6 6.1 What is the role of bronchodilators in COPD? 52 SHORT-ACTING BETA AGONISTS 6.2 How do short-acting beta agonists work? 52 6.3 What are the indications for their use? 52 6.4 What is the

More information

GUIDELINE Sinusitis. David M. Poetker MD, MA Associate Professor. Division of Rhinology and Sinus Surgery

GUIDELINE Sinusitis. David M. Poetker MD, MA Associate Professor. Division of Rhinology and Sinus Surgery GUIDELINE Sinusitis David M. Poetker MD, MA Associate Professor Division of Rhinology and Sinus Surgery Guideline Fokkens et al. The European Position Paper on Rhinosinusitis and Nasal Polyps 2012. Rhinology.

More information

Prof. Florian Gantner. Vice President Respiratory Diseases Research Boehringer Ingelheim

Prof. Florian Gantner. Vice President Respiratory Diseases Research Boehringer Ingelheim Prof. Florian Gantner Vice President Respiratory Diseases Research Boehringer Ingelheim Research and Development in Practice: COPD Chronic Obstructive Pulmonary Disease (COPD) Facts Main cause of COPD

More information

Respiratory Concerns in Children with Down Syndrome

Respiratory Concerns in Children with Down Syndrome Respiratory Concerns in Children with Down Syndrome Paul E. Moore, M.D. Associate Professor of Pediatrics and Pharmacology Director, Pediatric Allergy, Immunology, and Pulmonary Medicine Vanderbilt University

More information

Canine Chronic Bronchitis Lisa Shearer DVM, DVSc, Diplomate ACVIM (internal medicine)

Canine Chronic Bronchitis Lisa Shearer DVM, DVSc, Diplomate ACVIM (internal medicine) Canine Chronic Bronchitis Lisa Shearer DVM, DVSc, Diplomate ACVIM (internal medicine) Chronic bronchitis (CB) is defined as a daily cough for greater than two months in which other causes of cough, such

More information

COPD is a multicomponent disease that includes. Inhaled Combination Therapy With Long-Acting 2 -Agonists and Corticosteroids in Stable COPD*

COPD is a multicomponent disease that includes. Inhaled Combination Therapy With Long-Acting 2 -Agonists and Corticosteroids in Stable COPD* Inhaled Combination Therapy With Long-Acting 2 -Agonists and Corticosteroids in Stable COPD* Mario Cazzola, MD, FCCP; and Ronald Dahl, MD Long-acting 2 -agonists (LABAs) have been shown to be effective

More information

COPD. Information brochure for chronic obstructive pulmonary disease.

COPD. Information brochure for chronic obstructive pulmonary disease. COPD Information brochure for chronic obstructive pulmonary disease. CONTENTS What does COPD mean?...04 What are the symptoms of COPD?...06 What causes COPD?...09 Treating COPD...10 Valve therapy in COPD...12

More information

COPD and Asthma Differential Diagnosis

COPD and Asthma Differential Diagnosis COPD and Asthma Differential Diagnosis Chronic Obstructive Pulmonary Disease (COPD) is the third leading cause of death in America. Learning Objectives Use tools to effectively diagnose chronic obstructive

More information

VPM 152. INFLAMMATION: Chemical Mediators

VPM 152. INFLAMMATION: Chemical Mediators General Pathology VPM 152 INFLAMMATION: Chemical Mediators CHEMICAL MEDIATORS OF INFLAMMATION Definition: any messenger that acts on blood vessels, inflammatory cells or other cells to contribute to an

More information

From the Text. Clinical Indications. Clinical Indications. RSPT 2217 Non-steroidal Anti-asthma Agents. RSPT 2317 Non-steroidal Antiasthma Agents

From the Text. Clinical Indications. Clinical Indications. RSPT 2217 Non-steroidal Anti-asthma Agents. RSPT 2317 Non-steroidal Antiasthma Agents From the Text RSPT 2317 Non-steroidal Antiasthma Agents Gardenhire Chapter 12 Key Terms and Definitions Page 226 Nonsteroidal Antiasthma Meds Table 12-1; page 228 Comparative Features of Antileukotriene

More information

Department of Surgery

Department of Surgery What is emphysema? 2004 Regents of the University of Michigan Emphysema is a chronic disease of the lungs characterized by thinning and overexpansion of the lung-like blisters (bullae) in the lung tissue.

More information

How To Treat Acute Bronchitis

How To Treat Acute Bronchitis Bronchitis in Adults and Children Kristen Lewis, MD Acute Bronchitis Cough, with or without phlegm Lasting less than 3 weeks Frequently associated with or preceded d by other upper respiratory symptoms

More information

Electronic patient diaries in clinical research

Electronic patient diaries in clinical research Topics Electronic diaries in Clinical Trials Electronic diaries versus Paper Electronic patient diaries in clinical research Case Study: Novel detection of exacerbations of COPD with patient reported outcome

More information

Asthma. SS Visser, Lung Unit, UP

Asthma. SS Visser, Lung Unit, UP Asthma SS Visser, Lung Unit, UP Contents Definition Disease Pattern Prevalence Mortality Etiology Pathogenesis Triggers of acute attacks Contents Pathophysiology Manifestations of Resp failure Diagnosis:

More information

Background information

Background information Background information Asthma Asthma is a complex disease affecting the lungs that can be managed but cannot be cured. 1 Asthma can be controlled well in most people most of the time, although some people

More information

Montelukast Sodium Singulair, Merck. Development and Pharmacology: 1

Montelukast Sodium Singulair, Merck. Development and Pharmacology: 1 Montelukast Sodium Singulair, Merck Development and Pharmacology: 1 Asthma is a chronic inflammatory disease of the airways that is complicated by episodes of acute inflammation. Even patients with mild

More information

Pulmonary Disorders. Chronic Obstructive Pulmonary Disease (COPD) Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disorders. Chronic Obstructive Pulmonary Disease (COPD) Chronic Obstructive Pulmonary Disease (COPD) RCS 6080 Medical and Psychosocial Aspects of Rehabilitation Counseling Pulmonary Disorders Chronic Obstructive Pulmonary Disease (COPD) Characterized by decreased expiratory airflow Reduction in expiratory

More information

Asthma in Infancy, Childhood and Adolescence. Presented by Frederick Lloyd, MD Palo Alto Medical Foundation Palo Alto, California

Asthma in Infancy, Childhood and Adolescence. Presented by Frederick Lloyd, MD Palo Alto Medical Foundation Palo Alto, California Asthma in Infancy, Childhood and Adolescence Presented by Frederick Lloyd, MD Palo Alto Medical Foundation Palo Alto, California Major Health Problem in Childhood Afflicts 2.7 million children in the USA

More information

Guideline on the clinical investigation of medicinal products for the treatment of asthma

Guideline on the clinical investigation of medicinal products for the treatment of asthma 22 October 2015 CHMP/EWP/2922/01 Rev.1 Committee for Medicinal Products for Human Use (CHMP) Guideline on the clinical investigation of medicinal products for the treatment of Draft Agreed by Respiratory

More information

COPD It Can Take Your Breath Away www.patientedu.org

COPD It Can Take Your Breath Away www.patientedu.org written by Harvard Medical School COPD It Can Take Your Breath Away www.patientedu.org What Is COPD? COPD stands for chronic obstructive pulmonary disease. There are 2 major diseases included in COPD:

More information

Chronic Medications for Maintenance of Lung Health

Chronic Medications for Maintenance of Lung Health AJRCCM Articles in Press. Published on August 29, 2007 as doi:10.1164/rccm.200705-664oc Cystic Fibrosis Pulmonary Guidelines: Chronic Medications for Maintenance of Lung Health Patrick A. Flume, M.D. 1,

More information

Interpretation of Pulmonary Function Tests

Interpretation of Pulmonary Function Tests Interpretation of Pulmonary Function Tests Dr. Sally Osborne Cellular & Physiological Sciences University of British Columbia Room 3602, D.H Copp building 604 822-3421 sally.osborne@ubc.ca www.sallyosborne.com

More information

Severe asthma Definition, epidemiology and risk factors. Mina Gaga Athens Chest Hospital

Severe asthma Definition, epidemiology and risk factors. Mina Gaga Athens Chest Hospital Severe asthma Definition, epidemiology and risk factors Mina Gaga Athens Chest Hospital Difficult asthma Defined as asthma, poorly controlled in terms of chronic symptoms, with episodic exacerbations,

More information

CF ATLANTA Research & Development Program at Emory University and Georgia Tech (CF@LANTA) Clinical & Translational Research Core

CF ATLANTA Research & Development Program at Emory University and Georgia Tech (CF@LANTA) Clinical & Translational Research Core CF ATLANTA Research & Development Program at Emory University and Georgia Tech (CF@LANTA) Clinical & Translational Research Core Arlene Stecenko, MD Director, Emory + Children s Cystic Fibrosis Care Center

More information

Asthma. Micah Long, MD

Asthma. Micah Long, MD Asthma Micah Long, MD Goals Define the two components of asthma. Describe the method of action and uses for: Steroids (inhaled and IV) Quick Beta Agonists (Nebs and MDIs) The "Others" Magnesium, Epi IM,

More information

DRUG UTILISATION STUDY IN BRONCHIAL ASTHMA IN A TERTIARY CARE HOSPITAL

DRUG UTILISATION STUDY IN BRONCHIAL ASTHMA IN A TERTIARY CARE HOSPITAL International Journal of Pharmaceutical Applications ISSN 0976-2639, Online ISSN 2278 6023 Vol 3, Issue 2, 2012, pp 297-305 http://www.bipublication.com DRUG UTILISATION STUDY IN BRONCHIAL ASTHMA IN A

More information

Pathophysiology of asthma

Pathophysiology of asthma CHAPTER 5 Pathophysiology of asthma P.J. Barnes Correspondence: P.J. Barnes, Dept of Thoracic Medicine, National Heart and Lung Institute, Dovehouse St, London SW3 6LY, UK. Asthma is characterised by a

More information

Note for guidance on clinical investigation of medicinal products for treatment of asthma

Note for guidance on clinical investigation of medicinal products for treatment of asthma 1 2 3 27 June 2013 CHMP/EWP/2922/01 Rev.1 Committee for Medicinal Products for Human Use (CHMP) 4 5 6 Note for guidance on clinical investigation of medicinal products for treatment of asthma Draft Draft

More information

Effects of long-term clarithromycin treatment on lavagefluid markers of inflammation in chronic rhinosinusitis

Effects of long-term clarithromycin treatment on lavagefluid markers of inflammation in chronic rhinosinusitis Clin Physiol Funct Imaging (2009) 29, pp136 142 doi: 10.1111 Effects of long-term clarithromycin treatment on lavagefluid markers of inflammation in chronic rhinosinusitis Anders Cervin 1,2,4 MD, Ben Wallwork

More information

Recurrent or Persistent Pneumonia

Recurrent or Persistent Pneumonia Recurrent or Persistent Pneumonia Lower Respiratory Tract Dr T Avenant Recurrent or Persistent Pneumonia Definitions Recurrent pneumonia more than two episodes of pneumonia in 18 months Persistent pneumonia

More information

Wheezing in Children. Prof RJ Green Department of Paediatrics

Wheezing in Children. Prof RJ Green Department of Paediatrics Wheezing in Children Prof RJ Green Department of Paediatrics Adventitious Airway Sounds Snoring Stridor Wheezing Crepitations Airway Diameter Cause of Wheezing Not from obstruction of small airways Surface

More information

SARCOIDOSIS. Signs and symptoms associated with specific organ involvement can include the following:

SARCOIDOSIS. Signs and symptoms associated with specific organ involvement can include the following: SARCOIDOSIS Sarcoidosis is a disease that occurs when areas of inflammation develop in different organs of the body. Very small clusters of inflammation, called granulomas, are seen with sarcoidosis. They

More information

COPD PROTOCOL CELLO. Leiden

COPD PROTOCOL CELLO. Leiden COPD PROTOCOL CELLO Leiden May 2011 1 Introduction This protocol includes an explanation of the clinical picture, diagnosis, objectives and medication of COPD. The Cello way of working can be viewed on

More information

written by Harvard Medical School COPD It Can Take Your Breath Away www.patientedu.org/copd

written by Harvard Medical School COPD It Can Take Your Breath Away www.patientedu.org/copd written by Harvard Medical School COPD It Can Take Your Breath Away www.patientedu.org/copd What Is COPD? COPD stands for chronic obstructive pulmonary disease. There are two major diseases included in

More information

Medical Management of Nasal Polyposis

Medical Management of Nasal Polyposis Medical Management of Nasal Polyposis Camysha Wright, MD, MPH Faculty Advisor: Jing Shen, MD The University of Texas Medical Branch Department of Otolaryngology Grand Rounds Presentation April 23, 2008

More information

The asthmatic patient and sedation

The asthmatic patient and sedation The asthmatic patient and sedation Introduction The sedation practitioner is often faced with difficult questions to answer before the administration of sedation. Our guidelines say clearly that we are

More information

Management of exacerbations in chronic obstructive pulmonary disease in Primary Care

Management of exacerbations in chronic obstructive pulmonary disease in Primary Care Management of exacerbations in chronic obstructive pulmonary disease in Primary Care Acute exacerbations of chronic obstructive pulmonary disease (COPD) are associated with significant morbidity and mortality.

More information

Omega-3 fatty acids improve the diagnosis-related clinical outcome. Critical Care Medicine April 2006;34(4):972-9

Omega-3 fatty acids improve the diagnosis-related clinical outcome. Critical Care Medicine April 2006;34(4):972-9 Omega-3 fatty acids improve the diagnosis-related clinical outcome 1 Critical Care Medicine April 2006;34(4):972-9 Volume 34(4), April 2006, pp 972-979 Heller, Axel R. MD, PhD; Rössler, Susann; Litz, Rainer

More information

RESPIRATORY VENTILATION Page 1

RESPIRATORY VENTILATION Page 1 Page 1 VENTILATION PARAMETERS A. Lung Volumes 1. Basic volumes: elements a. Tidal Volume (V T, TV): volume of gas exchanged each breath; can change as ventilation pattern changes b. Inspiratory Reserve

More information

understanding the professional guidelines

understanding the professional guidelines SEVERE ASTHMA understanding the professional guidelines This guide includes information on what the European Respiratory Society (ERS) and the American Thoracic Society (ATS) have said about severe asthma.

More information

Medicines Use Review Supporting Information for Asthma Patients

Medicines Use Review Supporting Information for Asthma Patients Medicines Use Review Supporting Information for Asthma Patients What is asthma? Asthma is a chronic inflammatory disorder of the airways. The inflammation causes an associated increase in airway hyper-responsiveness,

More information

Understanding COPD. Carolinas Healthcare System

Understanding COPD. Carolinas Healthcare System Understanding COPD Carolinas Healthcare System 2013 This self-directed learning module contains information about the pathophysiology, diagnosis, and treatment of COPD. Target Audience: All RNs and LPNs

More information

Tests. Pulmonary Functions

Tests. Pulmonary Functions Pulmonary Functions Tests Static lung functions volumes Dynamic lung functions volume and velocity Dynamic Tests Velocity dependent on Airway resistance Resistance of lung tissue to change in shape Dynamic

More information

Technological platforms

Technological platforms Advitech Advitech is a life sciences & technology company Its mission is to discover and commercialize proprietary and evidence-based natural health products Focus on milk, whey and bovine colostrum R&D,

More information

These factors increase your chance of developing emphysema. Tell your doctor if you have any of these risk factors:

These factors increase your chance of developing emphysema. Tell your doctor if you have any of these risk factors: Emphysema Pronounced: em-fiss-see-mah by Debra Wood, RN En Español (Spanish Version) Definition Emphysema is a chronic obstructive disease of the lungs. The lungs contain millions of tiny air sacs called

More information

Allergies and Autoimmune Inner Ear Disease

Allergies and Autoimmune Inner Ear Disease Allergies and Autoimmune Inner Ear Disease Allergy is the term used to describe an over-reaction of the body to a substance that is normally harmless to most people. This substance is called an allergen,

More information

Outcome of asthma: longitudinal changes in lung function

Outcome of asthma: longitudinal changes in lung function Eur Respir J 1999; 13: 904±918 Printed in UK ± all rights reserved Copyright #ERS Journals Ltd 1999 European Respiratory Journal ISSN 0903-1936 REVIEW Outcome of asthma: longitudinal changes in lung function

More information

IN-HOME QUALITY IMPROVEMENT. BEST PRACTICE: DISEASE MANAGEMENT Chronic Obstructive Pulmonary Disease NURSE TRACK

IN-HOME QUALITY IMPROVEMENT. BEST PRACTICE: DISEASE MANAGEMENT Chronic Obstructive Pulmonary Disease NURSE TRACK IN-HOME QUALITY IMPROVEMENT BEST PRACTICE: DISEASE MANAGEMENT Chronic Obstructive Pulmonary Disease NURSE TRACK Best Practice Intervention Packages were designed for use by any In-Home Provider Agency

More information

YALE UNIVERSITY SCHOOL OF MEDICINE: SECTION OF OTOLARYNGOLOGY PATIENT INFORMATION FUNCTIONAL ENDOSCOPIC SINUS SURGERY

YALE UNIVERSITY SCHOOL OF MEDICINE: SECTION OF OTOLARYNGOLOGY PATIENT INFORMATION FUNCTIONAL ENDOSCOPIC SINUS SURGERY YALE UNIVERSITY SCHOOL OF MEDICINE: SECTION OF OTOLARYNGOLOGY PATIENT INFORMATION FUNCTIONAL ENDOSCOPIC SINUS SURGERY What is functional endoscopic sinus surgery (FESS)? Functional endoscopic sinus surgery

More information

Use of Azithromycin in Children with Non-Cystic Fibrosis Bronchiectasis or Chronic Suppurative Lung Disease

Use of Azithromycin in Children with Non-Cystic Fibrosis Bronchiectasis or Chronic Suppurative Lung Disease Use of Azithromycin in Children with Non-Cystic Fibrosis Bronchiectasis or Chronic Suppurative Lung Document ID CHQ-GDL-01061 Version no. 2.0 Approval date 28/08/2015 Executive sponsor Executive Director

More information

The Most Common Autoimmune Disease: Rheumatoid Arthritis. Bonita S. Libman, M.D.

The Most Common Autoimmune Disease: Rheumatoid Arthritis. Bonita S. Libman, M.D. The Most Common Autoimmune Disease: Rheumatoid Arthritis Bonita S. Libman, M.D. Disclosures Two googled comics The Normal Immune System Network of cells and proteins that work together Goal: protect against

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Afrezza Page 1 of 6 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Afrezza (human insulin) Prime Therapeutics will review Prior Authorization requests Prior Authorization

More information

Summary of the risk management plan (RMP) for Orkambi (lumacaftor and ivacaftor)

Summary of the risk management plan (RMP) for Orkambi (lumacaftor and ivacaftor) EMA/662624/2015 Summary of the risk management plan (RMP) for Orkambi (lumacaftor and ivacaftor) This is a summary of the risk management plan (RMP) for Orkambi, which details the measures to be taken

More information

Nasal polyps differ in terms of origin, as well

Nasal polyps differ in terms of origin, as well Focus on CME at the University of Saskatchewan Clearing the Air on Nasal Polyps By Gordon Franke, MD, BSc, FRCS(C) Presented at the University of Saskatchewan Practical Otolaryngology Conference 2003,

More information

ASTHMA IN INFANTS AND YOUNG CHILDREN

ASTHMA IN INFANTS AND YOUNG CHILDREN ASTHMA IN INFANTS AND YOUNG CHILDREN What is Asthma? Asthma is a chronic inflammatory disease of the airways. Symptoms of asthma are variable. That means that they can be mild to severe, intermittent to

More information

CLINICAL PATHWAY. Acute Medicine. Chronic Obstructive Pulmonary Disease

CLINICAL PATHWAY. Acute Medicine. Chronic Obstructive Pulmonary Disease CLINICAL PATHWAY Acute Medicine Chronic Obstructive Pulmonary Disease Chronic Obstructive Pulmonary Disease Table of Contents (tap to jump to page) INTRODUCTION 1 Scope of this Pathway 1 Pathway Contacts

More information

www.oil-testimonials.com COPD Now What?... Young Living!

www.oil-testimonials.com COPD Now What?... Young Living! www.oil-testimonials.com Horse with COPD Author: Bonnie Burch COPD Now What?... Young Living! One of my horses had COPD. The vet said he could give him steroids, but wasn't sure if it would help. I had

More information

MEDICATION GUIDE. SYMBICORT 80/4.5 (budesonide 80 mcg and formoterol fumarate dihydrate 4.5 mcg) Inhalation Aerosol

MEDICATION GUIDE. SYMBICORT 80/4.5 (budesonide 80 mcg and formoterol fumarate dihydrate 4.5 mcg) Inhalation Aerosol MEDICATION GUIDE SYMBICORT 80/4.5 (budesonide 80 mcg and formoterol fumarate dihydrate 4.5 mcg) Inhalation Aerosol SYMBICORT 160/4.5 (budesonide 160 mcg and formoterol fumarate dihydrate 4.5 mcg) Inhalation

More information

Disclosures. Consultant and Speaker for Biogen Idec, TEVA Neuroscience, EMD Serrono, Mallinckrodt, Novartis, Genzyme, Accorda Therapeutics

Disclosures. Consultant and Speaker for Biogen Idec, TEVA Neuroscience, EMD Serrono, Mallinckrodt, Novartis, Genzyme, Accorda Therapeutics Mitzi Joi Williams, MD Neurologist MS Center of Atlanta, Atlanta, GA Disclosures Consultant and Speaker for Biogen Idec, TEVA Neuroscience, EMD Serrono, Mallinckrodt, Novartis, Genzyme, Accorda Therapeutics

More information

Chronic Obstructive Pulmonary Disease Patient Guidebook

Chronic Obstructive Pulmonary Disease Patient Guidebook Chronic Obstructive Pulmonary Disease Patient Guidebook The Respiratory System The respiratory system consists of the lungs and air passages. The lungs are the part of the body where gases are exchanged

More information

Chronic Obstructive Pulmonary Disease (COPD) Programme

Chronic Obstructive Pulmonary Disease (COPD) Programme Integrated Care Pathway Chronic Obstructive Pulmonary Disease (COPD) Programme Patient Handbook Contents Preface... 1 What is COPD?... 3 What causes COPD?... 4 - Smoking... 4 - Air pollution... 4 - The

More information

Cystic Fibrosis. Cystic fibrosis affects various systems in children and young adults, including the following:

Cystic Fibrosis. Cystic fibrosis affects various systems in children and young adults, including the following: Cystic Fibrosis What is cystic fibrosis? Cystic fibrosis (CF) is an inherited disease characterized by an abnormality in the glands that produce sweat and mucus. It is chronic, progressive, and is usually

More information

Thought for the Day. Courage is not simply one of the virtues, but the form of every virtue at the testing point. ~ C. S. Lewis

Thought for the Day. Courage is not simply one of the virtues, but the form of every virtue at the testing point. ~ C. S. Lewis Thought for the Day Courage is not simply one of the virtues, but the form of every virtue at the testing point. ~ C. S. Lewis Anatomy & Physiology Bio 2401 Lecture Instructor: Daryl Beatty Section 2 Lecture

More information

On completion of this chapter you should be able to: discuss the stepwise approach to the pharmacological management of asthma in children

On completion of this chapter you should be able to: discuss the stepwise approach to the pharmacological management of asthma in children 7 Asthma Asthma is a common disease in children and its incidence has been increasing in recent years. Between 10-15% of children have been diagnosed with asthma. It is therefore a condition that pharmacists

More information

Sponsor Novartis Pharmaceuticals

Sponsor Novartis Pharmaceuticals Clinical Trial Results Database Page 1 Sponsor Novartis Pharmaceuticals Generic Drug Name Indacaterol Therapeutic Area of Trial Chronic Obstructive Pulmonary Disease (COPD) Indication studied: COPD Study

More information

The patient s response to therapy within the first hour in the Emergency Room is one of the most reliable ways to predict need for hospitalization.

The patient s response to therapy within the first hour in the Emergency Room is one of the most reliable ways to predict need for hospitalization. Emergency Room Asthma Management Algorithm The Emergency Room Asthma Management Algorithm is to be used for any patient seen in the Emergency Room with the diagnosis of asthma. (The initial history should

More information

U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER)

U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Guidance for Industry Acute Bacterial Exacerbations of Chronic Bronchitis in Patients With Chronic Obstructive Pulmonary Disease: Developing Antimicrobial Drugs for Treatment U.S. Department of Health

More information

Asthma Glossary. Allergen

Asthma Glossary. Allergen Action plan Acute Adverse Allergen Allergic asthma Allergic rhinitis Allergist Allergy Allergy shots Alveoli Anaphylaxis Antibiotic Antibodies Antihistamine Asthma Asthma Attack Breath sounds Bronchi (singular,

More information

A PRACTICAL APPROACH TO CHRONIC COUGH IN CHILDREN

A PRACTICAL APPROACH TO CHRONIC COUGH IN CHILDREN A PRACTICAL APPROACH TO CHRONIC COUGH IN CHILDREN Chng Seo Yi Chronic cough is defined as a persistent cough of more than three weeks duration which is not getting better. It is a common symptom in childhood.

More information

GUIDELINES. Canadian guidelines for the management of acute exacerbations of chronic bronchitis

GUIDELINES. Canadian guidelines for the management of acute exacerbations of chronic bronchitis GUIDELINES Canadian guidelines for the management of acute exacerbations of chronic bronchitis Meyer S Balter MD FRCPC 1, Jacques La Forge MD FRCPC CSPQ 2, Donald E Low MD FRCPC 1,3, Lionel Mandell MD

More information

Chapter 16: Innate Immunity

Chapter 16: Innate Immunity Chapter 16: Innate Immunity 1. Overview of Innate Immunity 2. Inflammation & Phagocytosis 3. Antimicrobial Substances 1. Overview of Innate Immunity The Body s Defenses The body has 2 types of defense

More information

Original Article COPD and Hospital Stay Pak Armed Forces Med J 2014; 64 (1): 46-50. Ahmed Raza, Mahmood Iqbal Malik*, Yousaf Jamal**

Original Article COPD and Hospital Stay Pak Armed Forces Med J 2014; 64 (1): 46-50. Ahmed Raza, Mahmood Iqbal Malik*, Yousaf Jamal** Original Article COPD and Hospital Stay Pak Armed Forces Med J 2014; 64 (1): 46-50 COMPARISON OF NIPPV WITH STANDARD TREATMENT IN PATIENTS WITH ACUTE EXACERBATIONS OF COPD IN TERMS OF IMPROVEMENT IN ABGS

More information

PTE Pediatric Asthma Metrics Reporting Updated January 2015

PTE Pediatric Asthma Metrics Reporting Updated January 2015 PTE Pediatric Asthma Metrics Reporting Updated January 20 Introduction: The Maine Health Management Coalition s (MHMC) Pathways to Excellence (PTE) Program is preparing for its next round of PTE Pediatric

More information

Etiology and treatment of chronic bacterial prostatitis the Croatian experience

Etiology and treatment of chronic bacterial prostatitis the Croatian experience Etiology and treatment of chronic bacterial prostatitis the Croatian experience Višnja Škerk University Hospital for Infectious Diseases "Dr. Fran Mihaljevic" Zagreb Croatia Milano, Malpensa, 14 Nov 2008

More information

Arterial Blood Gas Case Questions and Answers

Arterial Blood Gas Case Questions and Answers Arterial Blood Gas Case Questions and Answers In the space that follows you will find a series of cases that include arterial blood gases. Each case is then followed by an explanation of the acid-base

More information

An Overview of Asthma - Diagnosis and Treatment

An Overview of Asthma - Diagnosis and Treatment An Overview of Asthma - Diagnosis and Treatment Asthma is a common chronic disorder of the airways that is complex and characterized by variable and recurring symptoms, airflow obstruction, bronchial hyperresponsiveness,

More information

Circular Instructions related to occupational lung diseases

Circular Instructions related to occupational lung diseases Circular Instructions related to occupational lung diseases Compensation Fund Dr Monge Lekalakala OCCUPATIONAL DISEASES According to Section 65(1) of the COID ACT: a) An Occupational disease disease arising

More information

9/16/2014. Anti-Immunoglobulin E (IgE) Omalizumab (Xolair ) Dosing Guidance

9/16/2014. Anti-Immunoglobulin E (IgE) Omalizumab (Xolair ) Dosing Guidance Disclosure Statement of Financial Interest New Therapies for Asthma Including Omalizumab and Anti-Cytokine Therapies Marsha Dangler, PharmD, BCACP Clinical Pharmacy Specialist James H. Quillen VA Medical

More information

InetCE 146-000-01-001-H01

InetCE 146-000-01-001-H01 The National Asthma Education Prevention Program (NAEPP II) Guidelines for the Treatment of Asthma: Implications for the Pharmacist (Manuscript Updated December 2000) InetCE 146-000-01-001-H01 Theresa

More information

COPD MANAGEMENT PROTOCOL STANFORD COORDINATED CARE

COPD MANAGEMENT PROTOCOL STANFORD COORDINATED CARE I. PURPOSE To establish guidelines f the collabative management of patients with a diagnosis of chronic obstructive pulmonary disease (COPD) who are not adequately controlled and to define the roles and

More information

X-Plain Sinus Surgery Reference Summary

X-Plain Sinus Surgery Reference Summary X-Plain Sinus Surgery Reference Summary Introduction Sinus surgery is a very common and safe operation. Your doctor may recommend that you have sinus surgery. The decision whether or not to have sinus

More information